Clinical data technology and automation firm Beaconcure has raised USD 14 million in a Series B funding round led by NewVale Capital, with participation from existing investors. This brings the total funds raised by the company to USD 16 million.

The funds will be used by the company to expand its market presence in the clinical data validation space, expand commercial operations, and launch its next-generation platform for clinicians, statistical programmers, and medical writers.

Post-funding the company appointed a strategic advisory board for oversight in the fields of clinical development, biostatistics, and regulation.

Israel and Massachusetts-based Beaconcure offers a clinical trial data management and validation platform called “Verify.” The platform is designed to independently verify, analyze, and validate clinical trial data and has been implemented across the top 10 pharmaceutical companies and Contract Research Organizations. The main objective of the platform is to shorten the data verification timeline from months to days, identify potential errors, and enable team collaboration within studies. The company’s solution has been used in studies such as Pfizer's Covid-19 vaccine trials.